Genmab — Maj 2020
-
Impressive.
-
amivantimab etc https://twitter.com/Jbauml/status/1266419491774349313
-
and the poster https://twitter.com/ivybelkins/status/1266419775347007489
-
Thank you E L for your dedication. We are so grateful for your work every day of the year here at PI.
-
Dr. Bahlis on opdated data of the MAIA trial in Multiple Myeloma. https://www.onclive.com/onclive-tv/dr-bahlis-on-updated-data-from-the-maia-trial-in-multiple-myeloma
-
Sc Dara submitted for japanese approval in Myeloma. https://www.onclive.com/web-exclusives/subcutaneous-daratumumab-submitted-for-japanese-approval-in-myeloma
-
Tusinde tak Bibob.
-
Hvad synes i om Amivantamab, når man ser denne sammenligning? På AE er der ingen tvivl, der er Amivantamab langt bedst, men hvad med effekt? https://twitter.com/jordiremon/status/1266434270005989377?s=21
-
Når man starter ud med de første patienter i fase 1/2 er det altid meget lave doser af hensyn til at være sikker på der ikke er alvorlige bivirkninger. De skruer så stille og roligt op for dosis. Af deres prækliniske modller har de allerede fastlagt hvad der synes at være den optimale dosis. Det KAN være det er 48mg. Det skal man så have testet i klinikken
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind